Merck One of Top Large-Cap Biopharma Picks-Analyst
Key takeaways
- Merck’s stronger‑than‑expected earnings and upbeat , coupled with promising clinical developments, are boosting its stock and positioning it as a leading biopharma play.
guidance
What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.
- Adjusted $2.49 vs. $2.08 consensus
EPS
Earnings per share — profit for one share of the company, in dollars.
- Revenue $18.085 billion vs. $17.313 billion consensus
- Sales timing boost $550 million
What happened
Merck & Co. Inc. (MRK) reported third‑quarter earnings that beat expectations, posting adjusted earnings of $2.49 per share versus analysts’ forecast of $2.08 and revenue of $18.085 billion, up 5% year‑over‑year and ahead of the $17.313 billion consensus. The company also lifted its fiscal 2026 What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Why it matters
The earnings beat and higher What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Short-term and longer-term
Short-term. Over the next few days, watch for Merck’s stock reaction to the FDA decision on Sac‑TMT, scheduled for June 15, and any updates from the CHORUS trial.
Longer-term. For the next several months, Merck’s pipeline developments—especially the neoantigen therapy and Sac‑TMT—could drive sustained earnings growth.
Words on this card
- Adjusted earnings
- Net income per share after excluding one‑time items
- Priority review
- A faster FDA review process for drugs that address unmet medical needs
- Phase 3
- The final stage of clinical trials before a drug can be approved
- Keytruda
- Merck’s leading immunotherapy drug for cancer
- ESMO
- European Society for Medical Oncology, a major oncology conference
- Guidance
- What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.